Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW TUCKER KUYKENDALL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1154697738
CMS profile
1381292
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$66,627.49

60 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $53,892.50 22
Travel and Lodging $7,717.47 19
Honoraria $3,953.52 3
Food and Beverage $1,064.00 16

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $18,177.50 12
Incyte Corporation $18,158.31 22
Takeda Pharmaceuticals U.S.A., Inc. $18,147.44 14
Karyopharm Therapeutics Inc. $6,552.59 7
Blueprint Medicines Corporation $2,948.00 1
Geron Corporation $2,643.65 4

Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW TUCKER KUYKENDALL

NPI 1154697738 · CMS profile ID 1381292

Allopathic & Osteopathic Physicians / Internal Medicine

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154697738?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW TUCKER KUYKENDALL, NPI 1154697738, CMS profile ID 1381292. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154697738?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ANDREW TUCKER KUYKENDALL, NPI 1154697738, CMS profile ID 1381292. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154697738?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ANDREW TUCKER KUYKENDALL, NPI 1154697738, CMS profile ID 1381292, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1154697738?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

60 matching records · $66,627.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 60 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–60 of 60.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $567.0406/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224100867 CMS
Blueprint Medicines Corporation $2,948.0006/13/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1235820396 CMS
Geron Corporation $102.3205/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238890442 CMS
Takeda Pharmaceuticals U.S.A., Inc. $127.2105/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223943460 CMS
Karyopharm Therapeutics Inc. $407.5005/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1246642221 CMS
Merck Sharp & Dohme LLC $1,220.0005/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238008470 CMS
Geron Corporation $27.4705/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238890440 CMS
Merck Sharp & Dohme LLC $2,440.0004/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238036082 CMS
Merck Sharp & Dohme LLC $3,965.0001/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238008480 CMS
Incyte Corporation $3,425.0001/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226067386 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,260.05 41
PY2020 $16,904.00 9
PY2021 $28,660.50 17
PY2022 $79,785.61 42
PY2023 $66,879.94 41
PY2024 $36,793.74 31
PY2025 $66,627.49 60

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $142.60 1
PY2025 Principal investigator $1,047,617.31 155
PY2024 Principal investigator $643,255.26 47
PY2023 Principal investigator $307,535.37 21
PY2022 Principal investigator $343,252.74 41
PY2021 Principal investigator $30,508.11 11
PY2020 Principal investigator $236,226.45 47
PY2019 Principal investigator $59,790.22 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

156 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,312.00 12/29/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175392910
Principal investigator 1 Janssen Research & Development, LLC $504.00 12/26/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393660
Principal investigator 1 SANOFI US SERVICES INC. $636.00 12/24/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 1226146216
Principal investigator 1 Janssen Research & Development, LLC $76,530.50 12/22/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393752
Principal investigator 1 SANOFI US SERVICES INC. $530.00 12/18/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 1226146212
Principal investigator 1 Janssen Research & Development, LLC $252.00 12/15/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175394088
Principal investigator 1 Incyte Corporation $60.00 12/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms No dispute reported 06/30/2026 1240476629
Principal investigator 1 Janssen Research & Development, LLC $2,352.00 12/01/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393970
Principal investigator 1 Janssen Research & Development, LLC $636.00 11/24/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393718
Principal investigator 1 Janssen Research & Development, LLC $252.00 11/24/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393910
Principal investigator 1 Janssen Research & Development, LLC $2,327.00 11/24/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175394019
Principal investigator 1 SANOFI US SERVICES INC. $1,618.40 11/14/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN) No dispute reported 06/30/2026 1226146209
Principal investigator 1 Janssen Research & Development, LLC $145,801.40 11/10/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393466
Principal investigator 1 Janssen Research & Development, LLC $1,022.00 11/03/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393010
Principal investigator 1 Geron Corporation $204.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893971
Principal investigator 1 Geron Corporation $204.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893975
Principal investigator 1 Geron Corporation $204.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893979
Principal investigator 1 Geron Corporation $204.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893983
Principal investigator 1 Geron Corporation $266.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893987
Principal investigator 1 Geron Corporation $544.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893991
Principal investigator 1 Geron Corporation $3,156.83 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893995
Principal investigator 1 Geron Corporation $3,865.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893999
Principal investigator 1 Geron Corporation $204.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894003
Principal investigator 1 Geron Corporation $3,156.83 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894007
Principal investigator 1 Geron Corporation $136.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894011
Principal investigator 1 Geron Corporation $204.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894016
Principal investigator 1 Geron Corporation $3,552.18 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894021
Principal investigator 1 Geron Corporation $266.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894026
Principal investigator 1 Geron Corporation $204.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894030
Principal investigator 1 Geron Corporation $3,243.74 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894034
Principal investigator 1 Geron Corporation $266.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894037
Principal investigator 1 Geron Corporation $544.00 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894041
Principal investigator 1 Geron Corporation $3,552.18 10/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894046
Principal investigator 1 Janssen Research & Development, LLC $64,093.08 10/09/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393964
Principal investigator 1 SANOFI US SERVICES INC. $1,725.00 10/09/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN) No dispute reported 06/30/2026 1226146201
Principal investigator 1 Novartis Pharmaceuticals Corporation $61,890.58 10/08/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients No dispute reported 06/30/2026 1190314079
Principal investigator 1 SANOFI US SERVICES INC. $2,019.60 10/02/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN) No dispute reported 06/30/2026 1226146205
Principal investigator 1 SANOFI US SERVICES INC. $3,638.00 09/11/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN) No dispute reported 06/30/2026 1226146198
Principal investigator 1 Geron Corporation $204.00 08/27/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893943
Principal investigator 1 Geron Corporation $136.00 08/27/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893946
Principal investigator 1 Geron Corporation $3,552.18 08/27/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893951
Principal investigator 1 Geron Corporation $544.00 08/27/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893954
Principal investigator 1 Geron Corporation $68.00 08/27/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893959
Principal investigator 1 Geron Corporation $70.72 08/27/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893964
Principal investigator 1 Geron Corporation $3,156.83 08/27/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893967
Principal investigator 1 Janssen Research & Development, LLC $451.00 08/25/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393302
Principal investigator 1 Janssen Research & Development, LLC $4,218.00 08/18/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393734
Principal investigator 1 Janssen Research & Development, LLC $37,455.49 08/07/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393929
Principal investigator 1 SANOFI US SERVICES INC. $495.00 08/07/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN) No dispute reported 06/30/2026 1226146196
Recipient Novartis Pharmaceuticals Corporation $142.60 08/05/2025 Covered Recipient Physician CDAK539A12301 No dispute reported 06/30/2026 1190292616
Principal investigator 1 Janssen Research & Development, LLC $662.00 08/04/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175394065
Principal investigator 1 Geron Corporation $2,380.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893783
Principal investigator 1 Geron Corporation $5,614.76 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893787
Principal investigator 1 Geron Corporation $2,884.56 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893791
Principal investigator 1 Geron Corporation $2,884.56 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893799
Principal investigator 1 Geron Corporation $266.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893803
Principal investigator 1 Geron Corporation $3,118.89 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893808
Principal investigator 1 Geron Corporation $2,672.40 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893812
Principal investigator 1 Geron Corporation $3,156.83 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893816
Principal investigator 1 Geron Corporation $2,884.56 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893820
Principal investigator 1 Geron Corporation $2,884.56 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893825
Principal investigator 1 Geron Corporation $70.72 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893829
Principal investigator 1 Geron Corporation $3,118.89 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893834
Principal investigator 1 Geron Corporation $2,672.40 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893838
Principal investigator 1 Geron Corporation $266.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893842
Principal investigator 1 Geron Corporation $2,380.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893847
Principal investigator 1 Geron Corporation $5,614.76 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893851
Principal investigator 1 Geron Corporation $2,380.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893855
Principal investigator 1 Geron Corporation $3,118.89 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893857
Principal investigator 1 Geron Corporation $2,380.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893862
Principal investigator 1 Geron Corporation $544.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893866
Principal investigator 1 Geron Corporation $266.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893870
Principal investigator 1 Geron Corporation $70.72 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893874
Principal investigator 1 Geron Corporation $3,118.89 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893878
Principal investigator 1 Geron Corporation $2,884.56 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893883
Principal investigator 1 Geron Corporation $70.72 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893887
Principal investigator 1 Geron Corporation $70.72 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893891
Principal investigator 1 Geron Corporation $2,672.40 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893895
Principal investigator 1 Geron Corporation $204.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893900
Principal investigator 1 Geron Corporation $3,118.89 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893903
Principal investigator 1 Geron Corporation $3,715.38 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893906
Principal investigator 1 Geron Corporation $2,672.40 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893909
Principal investigator 1 Geron Corporation $3,118.89 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893913
Principal investigator 1 Geron Corporation $3,118.89 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893915
Principal investigator 1 Geron Corporation $136.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893919
Principal investigator 1 Geron Corporation $2,380.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893923
Principal investigator 1 Geron Corporation $266.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893927
Principal investigator 1 Geron Corporation $2,672.40 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893931
Principal investigator 1 Geron Corporation $141.44 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893935
Principal investigator 1 Geron Corporation $252.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893939
Principal investigator 1 Janssen Research & Development, LLC $687.00 07/21/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393290
Principal investigator 1 Janssen Research & Development, LLC $1,008.00 07/11/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175392876
Principal investigator 1 Janssen Research & Development, LLC $13,811.73 07/10/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393140
Principal investigator 1 Janssen Research & Development, LLC $18,365.91 06/30/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393185
Principal investigator 1 GlaxoSmithKline, LLC. $2,295.68 06/26/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS No dispute reported 06/30/2026 1192101495
Principal investigator 1 Blueprint Medicines Corporation $1,627.00 06/18/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ava + Aza Combo Trial No dispute reported 06/30/2026 1235785591
Principal investigator 1 Janssen Research & Development, LLC $14,432.45 06/09/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393584
Principal investigator 1 Janssen Research & Development, LLC $10,692.00 06/06/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175392921
Principal investigator 1 Janssen Research & Development, LLC $4,996.25 06/06/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393975
Principal investigator 1 Blueprint Medicines Corporation $7,946.04 06/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 1235785503
Principal investigator 1 Blueprint Medicines Corporation $1,618.40 06/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ava + Aza Combo Trial No dispute reported 06/30/2026 1235785587
Principal investigator 1 Blueprint Medicines Corporation $673.20 05/23/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ava + Aza Combo Trial No dispute reported 06/30/2026 1235785583
Principal investigator 1 Janssen Research & Development, LLC $28,458.54 05/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393355
Principal investigator 1 Geron Corporation $500.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893713
Principal investigator 1 Geron Corporation $1,224.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893717
Principal investigator 1 Geron Corporation $2,380.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893721
Principal investigator 1 Geron Corporation $2,380.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893725
Principal investigator 1 Geron Corporation $3,513.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893727
Principal investigator 1 Geron Corporation $3,228.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893731
Principal investigator 1 Geron Corporation $3,978.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893737
Principal investigator 1 Geron Corporation $141.44 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893742
Principal investigator 1 Geron Corporation $1,980.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893747
Principal investigator 1 Geron Corporation $252.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893755
Principal investigator 1 Geron Corporation $2,672.40 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893759
Principal investigator 1 Geron Corporation $266.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893763
Principal investigator 1 Geron Corporation $2,672.40 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893768
Principal investigator 1 Geron Corporation $252.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893772
Principal investigator 1 Geron Corporation $266.00 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893776
Principal investigator 1 Geron Corporation $141.44 04/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238893780
Principal investigator 1 Janssen Research & Development, LLC $252.00 04/21/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175394031
Principal investigator 1 Blueprint Medicines Corporation $2,807.00 04/17/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 1235785475
Principal investigator 1 Blueprint Medicines Corporation $264.00 04/04/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 1235785471
Principal investigator 1 Novartis Pharmaceuticals Corporation $93,843.14 04/02/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients No dispute reported 06/30/2026 1190296552
Principal investigator 1 Janssen Research & Development, LLC $1,052.00 03/17/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393214
Principal investigator 1 Janssen Research & Development, LLC $266.00 03/17/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393571
Principal investigator 1 Janssen Research & Development, LLC $2,847.00 03/17/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393723
Principal investigator 1 Janssen Research & Development, LLC $266.00 03/17/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175394059
Principal investigator 1 GlaxoSmithKline, LLC. $2,366.40 03/10/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS No dispute reported 06/30/2026 1192101503
Principal investigator 1 Janssen Research & Development, LLC $1,542.92 03/03/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393261
Principal investigator 1 Geron Corporation $2,672.40 02/28/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894361
Principal investigator 1 Geron Corporation $3,118.89 02/28/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894365
Principal investigator 1 Geron Corporation $2,672.40 02/28/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894369
Principal investigator 1 Geron Corporation $266.00 02/28/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894372
Principal investigator 1 Geron Corporation $5,614.76 02/28/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894376
Principal investigator 1 Geron Corporation $2,884.56 02/28/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894380
Principal investigator 1 Geron Corporation $3,711.44 02/28/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894384
Principal investigator 1 Geron Corporation $2,884.56 02/28/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894389
Principal investigator 1 Blueprint Medicines Corporation $3,110.00 02/24/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ava + Aza Combo Trial No dispute reported 06/30/2026 1235785579
Principal investigator 1 Geron Corporation $3,552.18 02/21/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894221
Principal investigator 1 Geron Corporation $252.00 02/21/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894225
Principal investigator 1 Geron Corporation $636.00 02/21/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894228
Principal investigator 1 Geron Corporation $70.72 02/21/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894231
Principal investigator 1 Geron Corporation $204.00 02/21/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894235
Principal investigator 1 Geron Corporation $136.00 02/21/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894240
Principal investigator 1 Geron Corporation $3,156.83 02/21/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894244
Principal investigator 1 Geron Corporation $204.00 02/21/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894248
Principal investigator 1 Geron Corporation $544.00 02/21/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894252
Principal investigator 1 Geron Corporation $141.44 02/21/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894256
Principal investigator 1 Janssen Research & Development, LLC $982.00 02/17/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175394050
Principal investigator 1 Novartis Pharmaceuticals Corporation $53,983.12 02/14/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients No dispute reported 06/30/2026 1190295725
Principal investigator 1 Janssen Research & Development, LLC $31,981.65 02/10/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393418
Principal investigator 1 Janssen Research & Development, LLC $47,178.00 01/27/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175392885
Principal investigator 1 Blueprint Medicines Corporation $768.00 01/16/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ava + Aza Combo Trial No dispute reported 06/30/2026 1235785575
Principal investigator 1 Janssen Research & Development, LLC $266.00 01/09/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175393081
Principal investigator 1 Janssen Research & Development, LLC $6,131.17 01/06/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms No dispute reported 06/30/2026 1175392943
Principal investigator 1 Novartis Pharmaceuticals Corporation $106,097.23 01/02/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients No dispute reported 06/30/2026 1190301191